About Bionova

Bionova Scientific™ is a biologics CDMO focused on developing and manufacturing recombinant protein products using mammalian cell culture processes.

Bionova was founded on a simple principle…

Bionova’s founders believed that the best way to build a scientific services business was to bring together top scientific talent, arm them with the best available tools, and set them loose in an agile, energized culture focused on solving difficult client problems. By building a company that could tackle the toughest biopharma challenges, Bionova we would position itself to excel on everyday projects too. Today, that vision lives in a world-class team and facility that delivers unmatched CDMO services for our clients.

Bionova is built on a three-part strategy

1. Talent

Bionova is dedicated to attracting and developing biopharmaceutical experts with extensive technical experience and deep industry knowledge across all stages of biopharmaceutical drug development, analytical sciences, quality and cGMP manufacturing.

2. Technology & Infrastructure

Bionova’s nearly 80,000 sq. ft. of CDMO facilities are equipped with an ever-growing list of state-of-the-art instruments and equipment. Our expanded capabilities will include cGMP biologics manufacturing, scheduled to launch in September 2021.

3. Culture

Bionova intentionally hires professionals who are passionate about their science and about serving clients. Once on board, they are encouraged to make client success the highest priority.

Our History

Bionova was founded by a team of scientists who saw a better way to deliver biologics process development and process characterization services. They were committed to building a business that clients could trust and rely upon. They also wanted to attract great scientific talent, give them great tools to work with, and build a workplace where people were empowered and energized to do great work and to share mutual respect for each other. They had spent time at big companies and were committed to not let meetings and bureaucracy slow them down.

Since those early days, Bionova has been on a transformative journey. Thanks to the contributions of our growing team of customer-focused specialists, Bionova is now a full-service biologics CDMO and is constructing a state-of-the-art commercial-ready GMP manufacturing facility. With the support of its private equity partner, Great Point Partners, Bionova is currently working towards launch of GMP operations in 2021. The company has already announced multiple GMP clinical supply contracts, despite the months of construction and commissioning that remain, a strong indicator of the trust that clients feel toward Bionova.

A major priority for Bionova’s leadership team continues to be nurturing a culture focused on caring for the best interest of the client’s programs while also ensuring scientific excellence. The flexible, boutique-like environment allows the Bionova team to make each client a priority. This client-first approach has enabled the company to cultivate a network of clients loyal to Bionova, resulting continued growth.